None of the four peptides is an FDA-approved drug, and none of the blends is approved for any use
Protocol design for combination studies should be based on mechanistic rationale and reviewed against available pharmacological data
10.1186/s12937-016-0186-5 82 Landis-PiwowarK
About this article Cite this article Lotfishokouh, M., Foroutan, T
The professional obligations of those administering it are far clearer and enforceable. If [medical professionals] provide treatments that are not supported by a responsible body of medical opinion, or fail to obtain properly informed consent, they may be exposed to clinical negligence claims Mr Reissner noted that, The General Medical Council may interest itself in whether [a healthcare provider] can be satisfied that there is sufficient evidence of the use of peptides for a clinical purpose
Insurance may or may not cover GLP-1 medications like semaglutide, and even when it does, prior authorization requirements and surprise fees can cause delays and financial stress